What You Should Know:

你应该知道的：

– Techmed startup

– 医疗科技初创公司

illumicell AI

illumicell AI

, founded by a team of Harvard-trained physician Michel Bielecki, former McKinsey consultant Jeyla Sadikova, and rocket engineer Loup Cordey, has secured $2M in pre-seed funding. The funding round was supported by a combination of healthcare operators, clinicians, and early-stage funds, including life science investors KOFA Healthcare, Harvard Phoenix Venture Fund, and MedTechSyndicates.

，由哈佛大学毕业的医生米歇尔·贝莱茨基、前麦肯锡顾问杰拉·萨迪科娃和火箭工程师卢普·科尔德共同创立，已获得200万美元的预种子轮融资。此轮融资得到了一批医疗行业从业者、临床医生以及早期基金的支持，其中包括生命科学投资者KOFA Healthcare、哈佛凤凰风险基金和MedTechSyndicates。

– The company aims to transform fluid-based diagnostics with its portable “lab scanner” and real-time AI platform, capable of analyzing cells and biomarkers within minutes.

这家公司旨在通过其便携式“实验室扫描仪”和实时人工智能平台，彻底改变基于流体的诊断方式，该平台能够在几分钟内分析细胞和生物标志物。

Net Health Announces Appointment of Christy Totin as Chief Financial Officer.

净健康宣布任命克里斯蒂·托廷为首席财务官。

– The initial product focuses on a portable sperm analysis scanner designed to redefine male fertility care and establish a broader infrastructure for cellular health data.

– 初始产品聚焦于一款便携式精子分析扫描仪，旨在重新定义男性生育健康护理，并建立更广泛的细胞健康数据基础设施。

Addressing a Critical Need in Male Fertility

解决男性生育能力的关键需求

The company highlights that while 1 in 6 couples globally experience infertility, less than 25% of men receive a proper fertility evaluation. In the U.S., a large number of sperm tests are referred by doctors and specialists, but only a limited number of clinics can process them, leading to delays for patients.  .

该公司指出，虽然全球每六对夫妇中就有一对面临不孕不育问题，但只有不到 25% 的男性接受了适当的生育能力评估。在美国，大量精子检测由医生和专家推荐，但只有少数诊所能够处理这些检测，导致患者等待时间延长。

illumicell AI’s technology, which includes a proprietary, portable imaging system and AI-driven algorithms, aims to resolve these bottlenecks by providing results 50 times faster and at 20 times lower cost, directly in any doctor’s office.

illumicell AI的技术包括一个专有的便携式成像系统和人工智能驱动的算法，旨在通过在任何医生办公室直接提供快50倍且成本低20倍的结果来解决这些瓶颈。

Dr. Michel Bielecki, co-founder and CEO of illumicell AI, emphasizes the potential to improve healthcare quality by enabling real-time, lab-grade fluid diagnostics in any doctor’s office, reducing wait times and costs for patients. He also notes that each test contributes to a feedback loop, aiding clinicians and training AI models.  .

illumicell AI的联合创始人兼首席执行官米歇尔·比莱茨基博士强调，通过在任何医生办公室实现即时、实验室级别的流体诊断，有潜力提高医疗质量，减少患者的等待时间和成本。他还指出，每次检测都有助于形成一个反馈循环，帮助临床医生并训练人工智能模型。

Expanding Beyond Fertility

扩展到生育能力之外

illumicell AI’s technology generates structured, labeled cell data with each scan. The company is building a real-time dataset in male reproductive health, currently comprising over 400,000 data points.

illumicell AI的技术每次扫描都会生成结构化、标注的细胞数据。该公司正在男性生殖健康领域构建一个实时数据集，目前包含超过40万个数据点。

This data has the potential to provide personalized fertility insights, including:

该数据有可能提供个性化的生育能力分析，包括：

Lifestyle-linked fertility changes over time

与生活方式相关的生育能力随时间变化

Fertility response to interventions

生育能力对干预措施的反应

Early detection of fertility decline

早期发现生育能力下降

While initially focused on fertility, illumicell AI’s platform has the potential to be applied to other bodily fluids, enabling real-time cellular intelligence across various healthcare fields.

虽然最初专注于生育领域，但 illumicell AI 的平台有潜力应用于其他体液，为各个医疗保健领域提供实时的细胞智能。

Early Progress and Future Plans

早期进展与未来计划

illumicell AI reports that its prototype has shown strong correlation to gold-standard lab results in clinical trials, outperforming legacy systems. The company has secured Letters of Intent (LOIs) with fertility clinics in the USA, Japan, and Switzerland, and plans to submit for FDA approval in 2026.

illumicell AI 报告称，其原型在临床试验中显示出与黄金标准实验室结果的高度相关性，性能优于传统系统。该公司已与美国、日本和瑞士的生育诊所签订了意向书（LOI），并计划于2026年提交FDA批准申请。

illumicell AI has also received recognition from innovation programs such as Harvard Innovation Labs, Creative Destruction Lab, MassChallenge Boston, Techstars, and Keihanna KGAP+ in Japan, and was acknowledged by the American Urological Association..

illumicell AI 还获得了哈佛创新实验室、创造性破坏实验室、MassChallenge波士顿、Techstars以及日本Keihanna KGAP+等创新项目的认可，并得到了美国泌尿协会的肯定。

“Fertility remains rooted in traditional approaches – still placing the burden of fertility almost entirely on women. It’s a bias that’s culturally driven and scientifically flawed,” added Jeyla Sadikova, co-founder at illumicell AI. “While 1 in 6 couples face infertility, the diagnostic and treatment focus is overwhelmingly centered on women – even though male factors are involved in up to half of all cases.

“生育能力仍然根植于传统方法——几乎将生育负担完全放在女性身上。这是一种文化驱动且科学上存在缺陷的偏见，”illumicell AI联合创始人杰拉·萨迪科娃补充道。“尽管六分之一的夫妻面临不孕问题，但诊断和治疗的重点却压倒性地集中在女性身上——即使男性因素在多达一半的案例中也起到作用。”

illumicell AI is changing that. We’re making fast, accurate, scalable male fertility diagnostics accessible anywhere, so diagnosis starts where it should: with both partners, equally.”.

illumicell AI 正在改变这一现状。我们正在让快速、准确、可扩展的男性生育能力诊断变得无处不在，从而让诊断从它应该开始的地方开始：即双方伴侣，平等对待。”